Clinical Trial Update: Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing safety and immunogenicity of the adjuvanted SCB-2019 SARS-CoV-2 vaccine in adults with chronic immune-mediated diseases was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune-mediated Diseases

Drugs mentioned

• SCB-2019 (SCB-2019 vaccine)

Snippet

Sponsor: Clover Biopharmaceuticals AUS Pty | Conditions: COVID-19 | Phase 3 | Status: TERMINATED